ICCC

IMMUCELL CORP /DE/ ICCC

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #1,653 of 2,925

Why it scores 50Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$7.19M

Quarter to Jun 30

Net income

$1.83M

Quarter to Jun 30

Free cash flow

$2.29M

Quarter to Jun 30

Operating margin

26.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$13.40M total
VANGUARD CAPITAL MANAGEMENT LLC
$2.69M+3.0%
MORGAN STANLEY
$2.35M+5.5%
RENAISSANCE TECHNOLOGIES LLC
$1.72M+12.7%
Cresset Asset Management, LLC
$1.36M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$726.5K+9.9%
DIMENSIONAL FUND ADVISORS LP
$587.4K+4.3%
Bleichroeder LP
$502.5K-50.8%
Steadtrust LLC
$456.0K-16.6%
Mesirow Financial Investment Management, Inc.
$426.9K0.0%
CITADEL ADVISORS LLC
$407.1K+13.5%
VANGUARD FIDUCIARY TRUST CO
$379.5K-11.5%
Strategic Financial Services, Inc.
$371.9K0.0%
HighTower Advisors, LLC
$244.8K0.0%
BlackRock, Inc.
$229.7K+25.7%
JANE STREET GROUP, LLC
$158.3KNew
Quadrature Capital Ltd
$154.9KNew
NORTHERN TRUST CORP
$147.9K-64.6%
MERCER GLOBAL ADVISORS INC /ADV
$120.6KNew
BAILARD, INC.
$101.5K0.0%
Militia Capital Management LLC
$100.5K-44.4%
SHUFRO ROSE & CO LLC
$100.5K-71.4%
HM PAYSON & CO
$40.2K0.0%
UBS Group AG
$10.1K-10.2%
OSAIC HOLDINGS, INC.
$3.9K0.0%
FMR LLC
$1.6KNew
See all 31 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ICCC

Earnings Per Share

13fpro.ai/company/ICCC

Loading ratio trend…

ICCC key financials by period

Reported revenue, net income and operating margin by fiscal year, from IMMUCELL CORP /DE/'s annual filings on SEC EDGAR.

IMMUCELL CORP /DE/ reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$27.6M$-1.0M6.0%
FY 2024$26.5M$-2.2M-6.2%
FY 2023$17.5M$-5.8M-32.9%
FY 2022$18.6M$-2.5M-12.4%
FY 2021$19.2M$-78.3K1.3%
FY 2020$15.3M$-1.0M-9.0%
Source: ICCC filings on SEC EDGAR →

Companies similar to ICCC

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

ICCC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About IMMUCELL CORP /DE/ (ICCC): stock profile, AI score and financials

IMMUCELL CORP /DE/ (ICCC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICCC at 49.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,653 of 2,925 stocks — the bottom half of the AI-ranked universe. ICCC scores in the top quartile across earnings quality (97.6). Areas of concern include revenue scale (5.7) and institutional flow (22.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), IMMUCELL CORP /DE/ reports quarterly revenue of $7.2M, net income of $1.8M, an operating margin of 26.9%. Top institutional holders of ICCC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ICCC trades on the Nasdaq exchange and files with the SEC under CIK 811641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUCELL CORP /DE/ directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 811641 →